Mini Oral session – Gynaecological cancers

Prof Dr Christine Gennigens, a medical oncologist at the University Hospital of CHU de Liège, focused on two studies presented during the mini oral session 2 on gynaecological cancers.

The phase 2, multicenter, open-label TROPION-PanTumor03 trial consists of distinct cohorts designed to evaluate the TROP2-targeting ADC datopotamab deruxtecan (Dato-DXd) as both monotherapy and in combination therapies across various tumour types. At ESMO, findings from the monotherapy cohorts in ovarian and endometrial cancers were presented. The study included patients with metastatic or unresectable recurrent disease who had received at least one prior platinum-based chemotherapy regimen. In terms of safety, adverse events of ≥ grade 3 were reported in approximately 54–57% of patients, with stomatitis, nausea, and alopecia being the most commonly observed toxicities. Despite these adverse events, treatment discontinuations were infrequent, occurring in approximately 5% of cases.

The phase 2 PICCOLO trial investigated the efficacy of mirvetuximab soravtansine (MIRV), an ADC targeting FRα in patients with recurrent platinum-sensitive ovarian cancer exhibiting high FRα expression. MIRV has previously received FDA approval for use in platinum-resistant ovarian cancer. This study focused on its application in the platinum-sensitive recurrent setting, involving patients who had undergone at least two prior lines of therapy, including taxanes, PARP inhibitors and bevacizumab. The primary endpoint was ORR, which was approximately 52%, comprising 6 complete responses and 35 partial responses. The most frequently reported adverse events were ocular toxicity and nausea.